{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-064390","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.930474+00:00","generated_at":"2026-06-27T02:08:41.968475+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IO Biotech appoints David V. Smith to Board of Directors effective March 1, 2022","bullets":["Smith appointed to Board and Audit Committee effective March 1, 2022.","Annual director retainer $40,000; Audit Committee fee $7,500; receives 28,019 stock options vesting over 3 years.","Smith is former EVP & CFO of Five Prime Therapeutics (acquired by Amgen) with 30+ years biotech leadership.","No related-party transactions or arrangements regarding his selection as director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-064390","json":"https://secwatch.observer/filing/0001193125-22-064390.json","markdown":"https://secwatch.observer/filing/0001193125-22-064390.md","text":"https://secwatch.observer/filing/0001193125-22-064390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/0001193125-22-064390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/d304399d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:08:41.968475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df2b1e77df","claim":"David V. Smith was appointed as Director at IO Biotech, Inc..","evidence_excerpt":"On February 28, 2022, the Board of Directors of IO Biotech, Inc. (the “Company”) appointed David V. Smith as a director of the Company, effective as of March 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522064390/0001193125-22-064390-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}